Mortality rates of melanoma are predicted to fall by 2050, but the number of individuals dying from the disease will increase due to population growth and ageing.
Findings of two studies presented recently at the European Cancer Congress 2017 (ECCO 2017) demonstrates the effect of the PD-1 inhibitor, pembrolizumab, against a rare form of melanoma and bladder cancer.
Three investigators from the University of Hong Kong (HKU), one from the Chinese University of Hong Kong (CUHK) and one from the Hong Kong University of Science and Technology (HKUST) received the prestigious Croucher Senior Medical Research Fellowship and Croucher Innovation Awards.
The CUHK Medical Centre, a nonprofit, self-financed teaching hospital of the Chinese University of Hong Kong (CUHK), is expected to commence operation in the second quarter of 2020.
Pembrolizumab is cost-effective in the first-line treatment of advanced melanoma in Hong Kong compared with ipilimumab and standard chemotherapy, according to a study presented at the European Society for Medical Oncology (ESMO) Asia 2016 Congress held recently in Singapore.